Characteristics of 410 patients with PsA
| All (N=410) | Patients in self-defined REM (n=88) | Patients in self-defined LDA (n=180) | Patients in other disease states (n=142) | |
| Male, n (%) | 208 (50.7) | 58 (65.9) | 95 (52.8) | 55 (38.7) |
| Mean age, years (SD) | 53.9 (12.5) | 53.7 (13.5) | 54.3 (12.3) | 53.4 (12.1) |
| Mean PsA duration, years (SD) | 11.2 (8.2) | 11.9 (8.7) | 11.3 (8.3) | 10.8 (7.9) |
| Mean level of schooling, years (SD) | 12.9 (3.4) | 13.4 (3.4) | 12.8 (3.5) | 12.6 (3.5) |
| Paid work, n (%) | 233 (56.8) | 53 (60.2) | 106 (58.9) | 74 (52.1) |
| Current smoking, n (%) | 68 (16.6) | 9 (10.2) | 25 (13.9) | 34 (23.9) |
| Elevated acute phase reactants (CRP >5 mg/L), n (%) | 156 (38.0) | 23 (26.1) | 60 (33.3) | 73 (51.4) |
| Radiographic lesions according to CASPAR criteria, n (%) | 124 (30.2) | 26 (29.5) | 51 (28.3) | 47 (33.1) |
| Conventional synthetic DMARD intake, n (%) | 243 (59.3) | 54 (61.4) | 112 (62.2) | 77 (54.2) |
| Biologic DMARD intake, n (%) | 233 (56.8) | 53 (60.2) | 108 (60.0) | 72 (50.7) |
| Oral glucocorticoids, n (%) | 67 (16.3) | 10 (11.4) | 26 (14.4) | 31 (21.8) |
| Number of comorbidities, mean (SD) | 1.3 (1.0) | 1.4 (1.1) | 1.2 (1.0) | 1.3 (1.0) |
| No current psoriasis skin lesions, n (%) | 142 (34.6) | 45 (51.1) | 63 (35.0) | 34 (23.9) |
| Body surface area of psoriasis ≥5%, n (%) | 38 (9.3) | 3 (3.4) | 14 (7.7) | 19 (13.3) |
| Tender entheseal points, LEI mean (SD) | 0.6 (1.4) | 0.4 (1.3) | 0.3 (0.9) | 1.1 (1.8) |
| Tender joint count (0–68), mean (SD) | 4.9 (9.8) | 3.4 (10.6) | 2.9 (6.8) | 8.4 (11.5) |
| Swollen joint count (0–66), mean (SD) | 2.4 (7.3) | 0.9 (3.6) | 1.6 (5.6) | 4.3 (10.0) |
| Physician’s global assessment of PsA, mean (SD) | 3.1 (2.5) | 1.7 (2.0) | 2.6 (2.1) | 4.7 (2.4) |
| Patient’s assessment of pain (0–10), mean (SD) | 4.1 (2.8) | 2.2 (2.4) | 3.5 (2.3) | 6.2 (2.2) |
| Patient’s global assessment of PsA (0–10), mean (SD) | 4.2 (2.8) | 2.4 (2.5) | 3.5 (2.2) | 6.2 (2.3) |
| DAPSA, mean (SD) | 17.0 (17.7) | 9.4 (15.5) | 12.8 (15.0) | 27.0 (17.8) |
| DAPSA<28, n (%) | 344 (83.9) | 84 (95.5) | 167 (92.8) | 49 (65.5) |
| HAQ (0–3), mean (SD) | 0.68 (0.68) | 0.36 (0.53) | 0.54 (0.58) | 1.06 (0.70) |
| PsAID 12, mean (SD) | 3.4 (2.5) | 1.8 (1.9) | 2.8 (2.1) | 5.2 (2.1) |
CASPAR, Classification Criteria for Psoriatic Arthritis; CRP, Creactive protein; DAPSA, Disease Activity Index for PSoriatic Arthritis; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; LDA, low disease activity; LEI, Leeds Enthesitis Index; PsA, psoriatic arthritis; PsAID, PsA Impact of Disease; REM, remission.